Skip to content
stoqly
en · USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 27, 2026.

Sign in

Lam Research

LRCX Nasdaq Semiconductor Materials & Equipment Financials FY2017–FY2026

Lam Research, based in Fremont, California, makes the machines that chipmakers use to build semiconductors on silicon wafers, and sells service for them. Its customers are memory, foundry and other chip manufacturers, which make chips for phones, computers, servers, cars and data storage. Its most significant customers in recent years have been Micron, Samsung, SK hynix and TSMC.

Today
3.2%
Previous close
$230.10
Market cap
$298.3B
P/E
35.4x
Fair value (model)
$72.02 −70% vs price
52-week range
$139.59 $433.33

Last close · Oct 26, 2026

$237.50

+$85.82 (+56.58%) past year

Share price

Lam Research

What Lam Research does

LRCX · Semiconductor Materials & Equipment

From its latest annual report

Lam Research, based in Fremont, California, makes the machines that chipmakers use to build semiconductors on silicon wafers, and sells service for them. Its customers are memory, foundry and other chip manufacturers, which make chips for phones, computers, servers, cars and data storage. Its most significant customers in recent years have been Micron, Samsung, SK hynix and TSMC.

Its equipment covers three main steps. Deposition tools lay down thin layers of metal and insulating material. Etch tools cut patterns into those layers. Clean tools remove particles and residue between steps. It also sells tools for advanced chip packaging and for a newer dry process for the photoresist (the light-sensitive layer used to print circuit patterns). Its Customer Support Business Group sells services, spare parts, upgrades, and new and refurbished older-generation tools to keep customers' installed equipment running.

Lam says chipmakers are moving to three-dimensional chip designs, which makes manufacturing more complex and drives demand for its tools. A large share of its sales and operations is outside the United States. It assembles and tests systems mostly in cleanrooms and outsources parts of manufacturing, warehousing and logistics to other companies.

Filing details

Legal name
LAM RESEARCH CORPORATION
Fiscal year ends
June 28, 2026
Latest annual report
10-K · Aug 7, 2026
Accession · CIK
0000707549-26-000037 · 0000707549
Biggest risks, in its own words

Earnings calendar · Lam Research

Every quarter, companies publish how much they sold and earned. These are the days Lam Research did it, and the next one. Share prices often move a lot on those days.

Next results

January 27, 2027

Wednesday · in 92 days

Time
After the market closes
Covers
Period ended Dec 27, 2026
Source
Stoqly estimate

Estimated from the same quarter last year. It will be replaced by the announced date once there is one.

See who else reports that week →
Date Results for Time Source
Oct 21, 2026 Q1 '27 After the market closes 8-K ↗
Jul 29, 2026 Q4 '26 After the market closes 8-K ↗
Apr 22, 2026 Q3 '26 After the market closes 8-K ↗
Jan 28, 2026 Q2 '26 After the market closes 8-K ↗
Oct 22, 2025 Q1 '26 After the market closes 8-K ↗
Jul 30, 2025 Q4 '25 After the market closes 8-K ↗
Apr 23, 2025 Q3 '25 After the market closes 8-K ↗
Jan 29, 2025 Q2 '25 After the market closes 8-K ↗

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Lam Research’s latest annual report (fiscal 2026). Here is what stands out:

7 strengths

1.Sales and profit

See section →
  • Lam Research had $23.2B of revenue in fiscal 2026, up 26.0% on the year before. Over five years, revenue changed +9.7% a year on average.
  • Its operating margin was 35.3%, up 3.3 pts: of every 100 in sales, about 35 is left after running the business.
  • Lam Research made $7.3B of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 22.6% a year.

2.Cash and shareholders

See section →
  • Free cash flow was $4.9B in fiscal 2026, 21.1% of revenue.
  • Lam Research returned $5.1B to shareholders in fiscal 2026, 105% of free cash flow. The diluted share count fell 2.3%.
  • In the last 12 months, insiders sold $176M of shares on the open market and bought none.

3.Financial health

See section →
  • Lam Research has $1.9B more cash than debt.
  • Its return on capital was 77.7%: every 100 invested in the business earned about 78 in a year.
  • Lam Research passes 8 of 9 financial health tests (Piotroski F-score).

4.Price and value

See section →
  • At $237.50 a share, the company is worth $298.3B: 35.4 times its earnings of the last four quarters.
  • Lam Research grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 2 of 2.

Biggest risks, in its own words

  • Chipmakers' spending on equipment that rises and falls sharply, so its sales are variable.
  • Relying on a limited number of key customers.
  • US export license rules and trade actions that affect its sales in China.
  • Rapid technology change that requires it to keep creating new products and processes.
  • Customers that tend to keep buying from the equipment maker they first chose, which makes new sales harder.

Lam Research in 30 seconds

Good So-so Weak

Good

Are sales growing?

+26.0%

Yes. Sales grew 26.0% last year.

Good

Does it make a profit?

31.3%

Yes. It keeps 31.3% of every sale as profit.

Good

Does profit turn into cash?

21.1%

Yes. 21.1% of sales ends up as free cash.

Good

Is debt under control?

Net cash

Yes. It has more cash than debt.

Good

How healthy are the accounts?

8 / 9

Solid. It passes 8 of 9 health tests.

For information

How is the share priced?

35.4x

One share costs 35.4 times its yearly profit per share. Typical for its sector: 33.0x.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2026

Market cap Last close times the latest diluted share count, so it is approximate.
$298.3B
Oct 26 close
P/E Last close divided by diluted earnings per share over the last four quarters.
35.4x
On $6.71 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA · Lam Research had $23.2B of revenue in fiscal 2026, up 26.0% on the year before. Over five years, revenue changed +9.7% a year on average.

See the full section →

Operating margin

Operating income as a share of revenue.

KIRA · Its operating margin was 35.3%, up 3.3 pts: of every 100 in sales, about 35 is left after running the business.

See the full section →

Net income

Profit after all expenses, interest and tax.

KIRA · Lam Research made $7.3B of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 22.6% a year.

See the full section →

Free cash flow

Cash from operations minus capital spending.

KIRA · Free cash flow was $4.9B in fiscal 2026, 21.1% of revenue.

See the full section →

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

KIRA · Its return on capital was 77.7%: every 100 invested in the business earned about 78 in a year.

See the full section →

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (10-for-1), so every year is on today's share basis.

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA summarises the numbers

  • Lam Research had $23.2B of revenue in fiscal 2026, up 26.0% on the year before.

    Over five years, revenue changed +9.7% a year on average.

  • Its operating margin was 35.3%, up 3.3 pts: of every 100 in sales, about 35 is left after running the business.

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Net income and earnings per share

Loss periods are shown in red.

KIRA summarises the numbers

  • Lam Research made $7.3B of net profit in fiscal 2026.

    From fiscal 2017 to 2026, diluted EPS grew 22.6% a year.

Net income

Net income

Diluted EPS

Diluted EPS

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

KIRA summarises the numbers

  • Free cash flow was $4.9B in fiscal 2026, 21.1% of revenue.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Dividends, buybacks and share count

KIRA summarises the numbers

  • Lam Research returned $5.1B to shareholders in fiscal 2026, 105% of free cash flow.

    The diluted share count fell 2.3%.

Dividends and buybacks

Dividends Buybacks

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

KIRA summarises the numbers

  • In the last 12 months, insiders sold $176M of shares on the open market and bought none.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$176M

8 insiders

Of sales under plans

77%

$136M

DateInsiderTradeSharesPriceValueFiling
Oct 23, 2026 Timothy ArcherPresident and CEO Sold plan 31,400 $227.02 $7.1M Form 4
Sep 9, 2026 Timothy ArcherPresident and CEO Sold plan 30,000 $319.26 $9.6M Form 4
Sep 9, 2026 Bethany MayerDirector Sold 9,557 $314.74 $3.0M Form 4
Sep 2, 2026 Seshasayee VaradarajanSenior Vice President Sold plan 59,750 $291.32 $17.4M Form 4
Aug 31, 2026 Ava HarterChief Legal Officer Sold plan 5,000 $302.46 $1.5M Form 4
Aug 6, 2026 Timothy ArcherPresident and CEO Sold plan 30,000 $300.00 $9.0M Form 4
Jul 13, 2026 Abhijit Y TalwalkarDirector Sold plan 18,282 $335.00 $6.1M Form 4
Jul 2, 2026 Timothy ArcherPresident and CEO Sold plan 30,000 $390.01 $11.7M Form 4
Jun 12, 2026 Eric BrandtDirector Sold plan 54,500 $367.18 $20.0M Form 4
Jun 11, 2026 Eric BrandtDirector Sold plan 54,500 $350.80 $19.1M Form 4
Jun 1, 2026 Neil J FernandesSenior Vice President Sold plan 7,659 $309.60 $2.4M Form 4
May 1, 2026 Neil J FernandesSenior Vice President Sold plan 18,170 $255.14 $4.6M Form 4
Apr 27, 2026 Ava HarterChief Legal Officer Sold 6,010 $258.66 $1.6M Form 4
Mar 4, 2026 Douglas R BettingerChief Financial Officer & EVP Sold 50,057 $224.03 $11.2M Form 4
Mar 4, 2026 Ava HarterChief Legal Officer Sold 1,500 $222.66 $0.3M Form 4
Mar 2, 2026 Douglas R BettingerChief Financial Officer & EVP Sold 40,329 $230.22 $9.3M Form 4
Mar 2, 2026 Ava HarterChief Legal Officer Sold 4,000 $232.50 $0.9M Form 4
Feb 6, 2026 Eric BrandtDirector Sold 35,000 $225.60 $7.9M Form 4
Dec 17, 2025 Timothy ArcherPresident and CEO Sold plan 163,300 $163.86 $26.8M Form 4
Nov 14, 2025 Douglas R BettingerChief Financial Officer & EVP Sold 40,080 $150.60 $6.0M Form 4
Nov 7, 2025 Bethany MayerDirector Sold plan 30 $159.52 $0.0M Form 4
Nov 3, 2025 Bethany MayerDirector Sold plan 1,298 $159.99 $0.2M Form 4
Oct 27, 2025 Ava HarterChief Legal Officer Sold 9,010 $157.47 $1.4M Form 4
Oct 13, 2025 Vahid VahediSenior Vice President Sold plan 52,190 $138.90 $7.2M Form 4

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Lam Research can carry it.

KIRA summarises the numbers

  • Lam Research has $1.9B more cash than debt.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $3.5B$5.3B$5.8B$6.4B$5.6B
Debt incl. finance leases $5.0B$5.0B$5.0B$4.5B$3.7B
Net debt / EBITDA 0.3x−0.1x−0.2x−0.3x−0.2x
Debt / equity 0.8x0.6x0.6x0.5x0.3x
Interest coverage 29.1x27.8x23.0x33.1x52.3x
Current ratio 2.7x3.2x3.0x2.2x2.6x
Quick ratio 1.8x2.0x2.0x1.6x1.9x
Total assets $17.2B$18.8B$18.7B$21.3B$23.5B
Total liabilities $10.9B$10.6B$10.2B$11.5B$11.1B
Shareholders' equity $6.3B$8.2B$8.5B$9.9B$12.5B
Net debt (− = net cash) $1.5B−$326M−$865M−$1.9B−$1.9B

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

KIRA summarises the numbers

  • Its return on capital was 77.7%: every 100 invested in the business earned about 78 in a year.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

KIRA summarises the numbers

  • Lam Research passes 8 of 9 financial health tests (Piotroski F-score).

TestFY24FY25FY26
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✕
Debt fell relative to assets ✓ ✓ ✓
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✓ ✓
Revenue rose relative to assets ✕ ✓ ✓
F-score 6 / 98 / 98 / 9
Accruals ratio −4.4%−4.1%6.3%
Altman Z'' 9.719.6311.07

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

Price and value

What does the share cost, and how does it compare?

Value Lam Research yourself

What could happen to the share if things go badly, normally or very well? Pick a story or make your own. These are examples, not forecasts or price targets.

KIRA summarises the numbers

  • At $237.50 a share, the company is worth $298.3B: 35.4 times its earnings of the last four quarters.

What if…? Five stories for the next 5 years

Tap one to see how it is built. Swipe for more.

Make your own scenario

Use the P/E of:

Share in 5 years

$367.42

+9% a year

If you put in $1,000 today: $1,547

At 34x, earnings only need to grow 0.8% a year for the share to be worth today’s price in 5 years. Faster, you gain; slower, you lose.

These are examples, not forecasts: nobody knows which will happen. Price in 5 years = earnings per share then × the P/E then. Dividends are not included.

Advanced models Discounted cash flow and a one-year earnings multiple, with every assumption to tune.

Discounted cash flow

Value per share

—

Adds net cash of $1.9B and divides by 1,261.1M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 34.3x · peers 32.9x · sector 33.0x.

In plain words: In the long run a share tends to follow two things: how much the company earns per share, and how many times those earnings the market is willing to pay (the P/E). Move those two levers and you see what the share could be worth. Different guesses give very different answers.

Similar companies

Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.

KIRA summarises the numbers

  • Lam Research grew sales faster than 4 of its 4 similar companies.

    Its P/E is higher than 2 of 2.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Lam Research LRCX $298.3B 26.0% 35.3% 21.1% 77.7% 35.4x 8
Applied Materials AMAT $310.1B 4.4% 29.2% 20.1% 35.9% 33.4x 7 Compare →
KLA KLAC $196.9B 11.7% — 27.7% 75.3% — 8 Compare →
Qnity Electronics Q $24.0B 9.7% — 20.8% 7.3% — — Compare →
MKS Instruments MKSI $14.7B 9.6% 13.4% 12.6% 7.9% 32.2x 6 Compare →

In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $8.0B $11.1B $9.7B $10.0B $14.6B $17.2B $17.4B $14.9B $18.4B $23.2B
Gross profit $3.6B $5.2B $4.4B $4.6B $6.8B $7.9B $7.8B $7.1B $9.0B $11.7B
Research and development $1.0B $1.2B $1.2B $1.3B $1.5B $1.6B $1.7B $1.9B $2.1B $2.4B
Operating income $1.9B $3.2B $2.5B $2.7B $4.5B $5.4B $5.2B $4.3B $5.9B $8.2B
Interest expense $118M $97.4M $117M $177M $209M $185M $187M $185M $178M $157M
Pretax income $1.8B $3.2B $2.4B $2.6B $4.4B $5.2B $5.1B $4.4B $6.0B $8.3B
Income tax $114M $771M $255M $323M $462M $588M $598M $532M $600M $997M
Net income $1.7B $2.4B $2.2B $2.3B $3.9B $4.6B $4.5B $3.8B $5.4B $7.3B
Diluted EPS $0.92 $1.32 $1.37 $1.51 $2.69 $3.27 $3.32 $2.90 $4.15 $5.76
Diluted shares 1.84B 1.81B 1.60B 1.49B 1.45B 1.41B 1.36B 1.32B 1.29B 1.26B
Cash flow
Cash from operations $2.0B $2.7B $3.2B $2.1B $3.6B $3.1B $5.2B $4.7B $6.2B $5.9B
Capital expenditure $157M $274M $304M $203M $349M $546M $502M $397M $759M $966M
Free cash flow $1.9B $2.4B $2.9B $1.9B $3.2B $2.6B $4.7B $4.3B $5.4B $4.9B
Depreciation and amortization $307M $326M $309M $269M $307M $334M $342M $360M $386M $442M
Stock-based compensation $150M $172M $187M $189M $220M $259M $287M $293M $343M $386M
Acquisitions $0.0M $116M $0.0M $0.0M $0.0M $0.0M $120M $0.0M $0.0M $0.0M
Share buybacks $812M $2.7B $3.8B $1.4B $2.7B $3.9B $2.0B $2.8B $3.4B $3.9B
Dividends paid $244M $308M $678M $657M $727M $815M $908M $1.0B $1.1B $1.3B
Dividends and buybacks $1.1B $3.0B $4.5B $2.0B $3.4B $4.7B $2.9B $3.9B $4.6B $5.1B
Balance sheet
Cash and short-term investments $2.4B $4.5B $3.7B $4.9B $4.4B $3.5B $5.3B $5.8B $6.4B $5.6B
Total debt $2.7B $2.4B $4.4B $5.8B $5.0B $5.0B $5.0B $5.0B $4.5B $3.7B
Finance lease liabilities $0.0M $0.0M $0.0M $15.2M $40.7M $43.4M $46.2M $16.0M $0.0M $0.0M
Current assets $9.1B $9.1B $8.6B $10.9B $11.7B $12.3B $13.2B $12.9B $14.5B $15.6B
Current liabilities $3.0B $3.2B $2.4B $3.2B $3.5B $4.6B $4.2B $4.3B $6.6B $5.9B
Inventory $1.2B $1.9B $1.5B $1.9B $2.7B $4.0B $4.8B $4.2B $4.3B $4.3B
Property and equipment, net $686M $903M $1.1B $1.1B $1.3B $1.6B $1.8B $2.1B $2.4B $2.9B
Total assets $12.1B $12.5B $12.0B $14.6B $15.9B $17.2B $18.8B $18.7B $21.3B $23.5B
Total liabilities $5.1B $5.9B $7.3B $9.4B $9.9B $10.9B $10.6B $10.2B $11.5B $11.1B
Shareholders' equity $6.8B $6.5B $4.7B $5.2B $6.0B $6.3B $8.2B $8.5B $9.9B $12.5B
Margins
Gross margin 45.0% 46.6% 45.2% 45.9% 46.5% 45.7% 44.6% 47.3% 48.7% 50.5%
Operating margin 23.7% 29.0% 25.5% 26.6% 30.6% 31.2% 29.7% 28.6% 32.0% 35.3%
EBITDA margin 27.6% 32.0% 28.7% 29.3% 32.7% 33.2% 31.7% 31.0% 34.1% 37.2%
Net margin 21.2% 21.5% 22.7% 22.4% 26.7% 26.7% 25.9% 25.7% 29.1% 31.3%
FCF margin 23.4% 21.5% 29.8% 19.2% 22.2% 14.8% 26.8% 28.6% 29.4% 21.1%
Returns
Return on capital — 42.3% 45.0% 40.6% 63.2% 66.4% 58.4% 48.1% 68.0% 77.7%
Return on capital employed 20.0% 34.7% 26.0% 25.4% 37.7% 43.1% 38.0% 29.4% 40.4% 50.7%
Return on equity 26.7% 35.8% 39.2% 45.7% 69.8% 74.9% 62.3% 45.7% 58.2% 65.1%
Return on assets 13.9% 19.4% 17.9% 17.0% 25.7% 27.8% 25.1% 20.4% 26.7% 32.4%
Growth
Revenue growth 36.2% 38.2% −12.9% 4.1% 45.6% 17.8% 1.2% −14.5% 23.7% 26.0%
Net income growth 85.7% 40.2% −8.0% 2.8% 73.6% 17.8% −2.1% −15.1% 40.0% 35.6%
EPS growth 77.0% 42.5% 4.0% 10.2% 78.2% 21.8% 1.4% −12.7% 43.1% 38.8%
FCF growth 59.3% 27.3% 20.6% −33.1% 68.4% −21.2% 83.2% −9.0% 27.2% −9.7%
Share count change 4.9% −1.6% −11.5% −6.8% −2.5% −3.2% −3.4% −2.8% −2.3% −2.3%
Financial health
Net debt / EBITDA 0.1x −0.6x 0.3x 0.3x 0.1x 0.3x −0.1x −0.2x −0.3x −0.2x
Debt / equity 0.4x 0.4x 1.0x 1.1x 0.8x 0.8x 0.6x 0.6x 0.5x 0.3x
Interest coverage 16.2x 33.0x 21.0x 15.1x 21.5x 29.1x 27.8x 23.0x 33.1x 52.3x
Current ratio 3.1x 2.9x 3.6x 3.4x 3.3x 2.7x 3.2x 3.0x 2.2x 2.6x
Quick ratio 2.7x 2.3x 3.0x 2.8x 2.5x 1.8x 2.0x 2.0x 1.6x 1.9x
Capital allocation
Capex / revenue 2.0% 2.5% 3.1% 2.0% 2.4% 3.2% 2.9% 2.7% 4.1% 4.2%
Stock comp / revenue 1.9% 1.6% 1.9% 1.9% 1.5% 1.5% 1.6% 2.0% 1.9% 1.7%
Payouts / FCF 56.4% 124.3% 155.2% 105.4% 105.7% 183.3% 62.5% 90.7% 84.4% 104.7%
Quality scores
Piotroski F-score 7.0 8.0 5.0 6.0 7.0 6.0 6.0 6.0 8.0 8.0
Altman Z'' 7.5 8.2 8.1 7.9 8.9 9.2 9.7 9.7 9.6 11.1
Accruals ratio −2.7% −2.2% −8.0% 0.9% 2.1% 9.1% −3.7% −4.4% −4.1% 6.3%

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Source: SEC EDGAR XBRL filings (CIK 0000707549). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open